Roots Analysis

MARCH 8, 2023

Over time, various research studies have demonstrated the potential of exosomes ( membrane bound extracellular vesicles) in disease diagnosis, drug delivery and therapeutic applications. Targeted Drug Delivery: Ability to cross blood brain barrier cause lesser systemic effects and low toxicity.

RNA 52

RNA Drug Delivery DNA Development 52

The Pharma Data

APRIL 8, 2021

Leadership in DNA damage response demonstrated in multiple presentations for AZD5305, a next-generation PARP1 selective inhibitor. Data for AZD5305 will demonstrate how the next wave of DNA damage response medicines can build on the success of PARP inhibitors, potentially allowing patients to stay on treatment longer.

DNA 52

DNA Medicine Genome Genomics 52

Drug Discovery World

JANUARY 17, 2023

Researchers developed nanoparticles able to penetrate the neural retina and deliver mRNA to the photoreceptor cells whose proper function makes vision possible. . The research aims to develop solutions for the limitations associated with adeno-associated virus (AAV), the current primary means of delivery for gene editing. .

Gene Editing 98

Gene Editing Gene Gene Therapy Genetics 98

The Pharma Data

JUNE 7, 2023

a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

Delveinsight

FEBRUARY 25, 2021

Beam adds to drug delivery stable with USD 120 Million GuideTx buy. The gene-editing technologies, which have reached the clinic, CRISPR, zinc finger nucleases, and TALENs, make their edits by nicking DNA at the target site. GuideTx will aid Beam in developing LNP-based medicines.

DNA 52

DNA In-Vivo Genetics Medicine 52

Roots Analysis

FEBRUARY 13, 2023

It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein. Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

Drug Discovery World

APRIL 29, 2024

Dr Andrew Lewis, Chief Scientific Officer; Kieron Hall, Chief Marketing Officer; and Eric Bironneau, Chief Business Officer, Quotient Sciences: Lewis has held various scientific leadership positions at Quotient and was previously Director of Novel Drug Delivery Technologies at Ipsen.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

pharmaphorum

OCTOBER 6, 2022

Click chemistry refers to molecular building blocks snapping together quickly and efficiently, and its development responded to the need to for pharmaceutical researchers to build increasingly complicated molecules. Barry Sharpless “for the development of click chemistry and bioorthogonal chemistry.” Bertozzi, Morten Meldal and K.

Drug Delivery 52

Drug Delivery DNA Medicine Research 52

Drug Discovery World

OCTOBER 18, 2023

Sara Donnelly, Director of Research Planning and Business Development at PhoenixBio USA explores why the right pre-clinical model is essential for teams wanting to advance adeno-associated virus vector-based gene therapies. Accelerate your gene therapy project Developing AAV vector-based gene therapies can be challenging.

Gene Therapy 64

Gene Therapy Gene Clinical Trials Clinical Trials 64

FDA Law Blog

JANUARY 5, 2023

The current Team Lead for Injection Devices in CDRH’s Division of Drug Delivery and General Hospital Devices and Human Factors noted that depending on the product, the pre-market path for a connected combination product might require an IND, IDE, or a determination that it is a medical device data system , which are not regulated as devices.

Regulation 59

Regulation Production Drug Delivery Insulin 59

Drug Discovery World

NOVEMBER 17, 2022

However, the development of drugs takes decades which is too long for most biotech start- ups looking for fast-track drug development programs. The company is developing a pan-European biotech studio network covering areas where synthetic biology can create disruptive solutions and high market value products.

Bacteria 52

Bacteria Engineer Gene Genetics 52

Roots Analysis

OCTOBER 22, 2023

In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. Furthermore, these drug candidates can be used to develop precise and individualized therapies that allow patients to produce therapeutic proteins in their own bodies.

RNA 40

RNA Protein Genetics Gene Expression 40

Drug Discovery World

NOVEMBER 9, 2023

The first three include: Sungjin Park, PhD, CEO, Onegene Biotechnology, on: ‘UniStac: Enzyme-mediated conjugation technology for accelerated development of tetraspecific NASH drug’. Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Roots Analysis

JANUARY 3, 2024

While numerous cardiovascular drug delivery devices and drug eluting stents are accessible for treating these conditions, treatment options for AF, including the anti-arrhythmic drugs, frequently prove ineffective. Most of the procedures under development can be done within an hour.

Marketing 40

Marketing Protein Drug Delivery Development 40

Delveinsight

SEPTEMBER 2, 2021

According to DelveInsight’s Neuromodulation Devices Market Analysis , the approval of this device will drive the market growth as around seven million people in the United States are currently living with stroke-related complications, and more than 80% of stroke survivors are estimated to develop gait impairment.

Marketing 72

Marketing Radiology Drugs Drug Delivery 72

XTalks

OCTOBER 1, 2020

And although academia and industry have often been pitted against each other in the realm of scientific discovery and development, there may be more similarities and synergies between the two than we may think. WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation.

Scientist 52

Scientist In-Vitro Research Life Science 52